Cargando…

Correction: Association of GWAS-Identified Lung Cancer Susceptibility Loci with Survival Length in Patients with Small-Cell Lung Cancer Treated with Platinum-Based Chemotherapy

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363696/ https://www.ncbi.nlm.nih.gov/pubmed/25781968 http://dx.doi.org/10.1371/journal.pone.0118689

Ejemplares similares

Association of GWAS-Identified Lung Cancer Susceptibility Loci with Survival Length in Patients with Small-Cell Lung Cancer Treated with Platinum-Based Chemotherapy
por: Li, Dong, et al.
Publicado: (2014)

Author Correction: GWAS for male-pattern baldness identifies 71 susceptibility loci explaining 38% of the risk
por: Pirastu, Nicola, et al.
Publicado: (2018)

Individual and Cumulative Effects of GWAS Susceptibility Loci in Lung Cancer: Associations after Sub-Phenotyping for COPD
por: Young, Robert P., et al.
Publicado: (2011)

GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer
por: Pharoah, Paul D. P., et al.
Publicado: (2013)

Genetic Susceptibility to Vitiligo: GWAS Approaches for Identifying Vitiligo Susceptibility Genes and Loci
por: Shen, Changbing, et al.
Publicado: (2016)

Validation of Susceptibility Loci for Vitiligo Identified by GWAS in the Chinese Han Population
por: Cheng, Lu, et al.
Publicado: (2020)

Integration of GWAS and eQTL Analysis to Identify Risk Loci and Susceptibility Genes for Gastric Cancer
por: Ni, Jing, et al.
Publicado: (2020)

Impact of metformin use on survival outcomes in non-small cell lung cancer treated with platinum
por: Wen-Xiu, Xin, et al.
Publicado: (2018)

Echocardiography and cardiac biomarkers in patients with non-small cell lung cancer treated with platinum-based chemotherapy
por: Omersa, Daniel, et al.
Publicado: (2016)

Replication Study for the Association of Seven Genome- Gwas-Identified Loci With Susceptibility to Ovarian Cancer in the Polish Population
por: Mostowska, Adrianna, et al.
Publicado: (2014)

The P38α rs3804451 Variant Predicts Chemotherapy Response and Survival of Patients with Non–Small Cell Lung Cancer Treated with Platinum-Based Chemotherapy()
por: Jia, Ming, et al.
Publicado: (2016)

NANOG as an adverse predictive marker in advanced non–small cell lung cancer treated with platinum-based chemotherapy
por: Chang, Boksoon, et al.
Publicado: (2017)

GWAS for male-pattern baldness identifies 71 susceptibility loci explaining 38% of the risk
por: Pirastu, Nicola, et al.
Publicado: (2017)

Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
por: Pons-Tostivint, E., et al.
Publicado: (2023)

Correction: Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in China
por: Liu, Huiqin, et al.
Publicado: (2023)

Circulating Survivin Protein Levels in Lung Cancer Patients Treated With Platinum-Based Chemotherapy
por: Puskas, Rita, et al.
Publicado: (2021)

Rechallenge with First-Line Platinum Chemotherapy for Sensitive-Relapsed Small-Cell Lung Cancer
por: Shiozawa, Toshihiro, et al.
Publicado: (2018)

Analysis of GWAS-nominated loci for lung cancer and COPD revealed a new asthma locus
por: Madore, Anne-Marie, et al.
Publicado: (2022)

Incidence of chemotherapy discontinuation and characteristics of elderly patients with non-small cell lung cancer treated with platinum-based doublets
por: Alexa, Teodora, et al.
Publicado: (2014)

CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy
por: Yi, Yonglin, et al.
Publicado: (2022)

Predictive value of EGFR mutation in non–small‐cell lung cancer patients treated with platinum doublet postoperative chemotherapy
por: Takahashi, Toshiaki, et al.
Publicado: (2021)

Environmental factors, seven GWAS‐identified susceptibility loci, and risk of gastric cancer and its precursors in a Chinese population
por: Cai, Meng, et al.
Publicado: (2017)

Author Correction: Gastroesophageal reflux GWAS identifies risk loci that also associate with subsequent severe esophageal diseases
por: An, Jiyuan, et al.
Publicado: (2019)

GWAS for autoimmune Addison’s disease identifies multiple risk loci and highlights AIRE in disease susceptibility
por: Eriksson, Daniel, et al.
Publicado: (2021)

Correction: Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis
por: Schad, Friedemann, et al.
Publicado: (2022)

The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of patients with advanced non-small cell lung cancer
por: Zhang, Jian-Wei, et al.
Publicado: (2014)

Association of the Geriatric Nutritional Risk Index with the survival of patients with non-small-cell lung cancer after platinum-based chemotherapy
por: Karayama, Masato, et al.
Publicado: (2021)

Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy
por: Brady, Anna K., et al.
Publicado: (2015)

GWAS identifies four novel eosinophilic esophagitis loci
por: Sleiman, Patrick MA, et al.
Publicado: (2014)

Genome-Wide Association Studies (GWAS) breast cancer susceptibility loci in Arabs: susceptibility and prognostic implications in Tunisians
por: Shan, Jingxuan, et al.
Publicado: (2012)

KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy
por: Marabese, Mirko, et al.
Publicado: (2015)

Roles of microRNAs in the resistance to platinum based chemotherapy in the non-small cell lung cancer
por: Zang, Hongjing, et al.
Publicado: (2017)

Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)
por: Kim, Hye Ryun, et al.
Publicado: (2017)

GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes
por: Nakayama, Akiyoshi, et al.
Publicado: (2017)

A radiomics prognostic scoring system for predicting progression-free survival in patients with stage IV non-small cell lung cancer treated with platinum-based chemotherapy
por: He, Lan, et al.
Publicado: (2021)

XRCC3 Thr241Met Is Associated with Response to Platinum-Based Chemotherapy but Not Survival in Advanced Non-Small Cell Lung Cancer
por: Qiu, Mantang, et al.
Publicado: (2013)

Overweight and Obesity are Associated with Poorer Survival Among Patients with Advanced Non-Small Cell Lung Cancer Receiving Platinum-Based Chemotherapy
por: Sutandyo, Noorwati, et al.
Publicado: (2023)

Unravelling the Roles of Susceptibility Loci for Autoimmune Diseases in the Post-GWAS Era
por: Ye, Jody, et al.
Publicado: (2018)

Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer
por: Baka, S, et al.
Publicado: (2008)

Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy
por: Shimizu, Katsuhiko, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9j84es26vpdh41jc14b3n3rd8v